|Bid||89.16 x 100|
|Ask||97.19 x 200|
|Day's Range||90.25 - 93.08|
|52 Week Range||66.00 - 97.98|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.35%|
Mergers have never been easy but these days companies have a new set of worries to add to the list. National security has become a potential hurdle after the potential merger of Broadcom (AVGO) and Qualcomm ...
The broader market scuffled in February, but the health care sector was worse. For example, the Health Care Select Sector SPDR (NYSE: XLV ) lost 4.5 percent, which was about 80 basis points worse than ...
The pharmaceutical industry is lobbying to reverse part of the recent Congressional spending bill that shifted a $10-billion consumer aid burden from the federal government to manufacturers. The Bipartisan ...
Key market index funds extended their gains Monday as Apple and Boeing led the Dow Jones industrial average.
With biotech stocks tumbling toward long-term levels of support, we take a closer look at how active traders will trade the bounce.
The Health Care Select Sector SPDR (NYSEArca: XLV), the largest exchange traded fund dedicated to the S&P 500’s third-largest sector weight, tumbled last week, but some market observers believe the decline ...
Panic is in the air; fear is on the rise. And that smug grin on bulls’ faces following such an epic start to 2018 is beginning to turn. Friday’s 2.54% drubbing in the Dow Jones Industrial Average has left many investors shell-shocked.
Trump described drug prices as “one of my greatest priorities,” but his administration has released nothing in the way of policy over the last year.
Array BioPharma (ARRY) is a biopharmaceutical company focused on discovery, development, and commercialization of small molecule drugs for the treatment of patients suffering from cancer. Of the nine analysts covering Array BioPharma (ARRY) in January 2018, eight have given the stock a “buy” or higher rating, and one has given it a “hold.” The mean rating for the stock is 1.78 with a target price of $16.22. Array BioPharma makes up 1.9% of the SPDR S&P Biotech ETF’s (XBI) total portfolio holdings.
The drug candidates in Radius Health’s (RDUS) pipeline include an investigational abaloparatide transdermal patch for possible use in treating women with postmenopausal osteoporosis. Another candidate is the investigational drug elacestrant (or RAD1901), which is a selective estrogen receptor degrader for the treatment of hormone receptor-positive breast cancer and the treatment of vasometer symptoms in postmenopausal women. The pipeline also includes the investigational drug RAD140, a nonsteroidal selective androgen receptor modulator, for its potential use in treating hormone receptor-positive breast cancer.
This article was originally published on ETF Trends.com. Biotechnology sector-related ETFs surged Monday after Celgene (NasdaqGS: CELG) said it will acquire Juno Therapeutics (NasdaqGS: JUNO) to expand ...
The largest exchange-traded fund to track the biotechnology sector rallied on Monday, supported by a pair of multibillion-dollar deals. The iShares Nasdaq Biotechnology ETF jumped 1.8%. At current levels, ...
Biotech stocks face a challenging 2018. Large companies are feeling pressed to do growth-spurring deals while the rally in smaller firms has pushed up their prices. And then there are the management teams ...
This article is a part of InvestorPlace’s Best ETFs for 2018 contest. Johnson Research Group’s pick for the contest is the SPDR S&P Biotech (ETF) (NYSEARCA:XBI). 2018 has gotten off to a roaring start, and biotechnology stocks are no exception.
In 3Q17, Bioverativ’s (BIVV) drug Alprolix generated revenue of $88.5 million, which reflected a rise of ~4% on a year-over-year (or YoY) basis. In 3Q17, Alprolix contributed ~32.2% of Bioverativ’s net product sales. Alprolix reported revenue of $264.2 million in the first nine months of 2017 (which ended in September 2017) compared to its revenue of $240.5 million in the first nine months of 2016.
On a day when the Dow's record high would normally be the top story, two 'Fast Money' traders discuss Wynn shares and what they bought Friday.